ConductScience.org, home

Paper30397355

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Imperial MZ and 10 others. Nat Med, 2018. Cited by 276 papers, by iCite.

Cite this record

ConductScience Library. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Papers, record 30397355. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30397355

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.
PubMed
Journal
Nat Med
PubMed
Year
2018
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
276
iCite
Relative citation ratio, by iCite
12.5
iCite
Revised in PubMed
2026-11-02
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Imperial MZMarjorie Z
2Nahid PPayam
3Phillips PPJPatrick P J
4Davies GRGeraint R
5Fielding KKatherine
6Hanna DDebra
7Hermann DDavid
8Wallis RSRobert S
9Johnson JLJohn L
10Lienhardt CChristian
11Savic RMRada Mhttps://orcid.org/0000-0003-3143-5579

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antitubercular AgentsMajor topic
Tuberculosis, Multidrug-ResistantMajor topic
Tuberculosis, PulmonaryMajor topic
Dose-Response Relationship, Drug
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Phenotype
Risk Factors
Sputum
Treatment Outcome

Source PubMed

Download CSV of topics

Grants7

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 AI104589NIAID NIH HHSUnited StatesR01AI104589PubMed and NIHNIH RePORTER
MR/K012126/1Medical Research CouncilUnited KingdomPubMedPubMed
R01 AI127300NIAID NIH HHSUnited StatesR01AI127300PubMedNIH RePORTER
T32 GM007175NIGMS NIH HHSUnited StatesT32GM007175PubMed and NIHNIH RePORTER
001World Health OrganizationInternationalPubMedPubMed
N01AI095383NIHNIH RePORTER
R01CA012126NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03941496Azacytidine During Anti-tuberculosis TherapyBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in30429542Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.https://conductscience.org/library/papers/30429542PubMed
Comment in30401868A stratified approach to tuberculosis treatment.https://conductscience.org/library/papers/30401868PubMed

Download CSV of comments and corrections

References19

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110529902Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.Int J Tuberc Lung Dis1999https://conductscience.org/library/papers/10529902PubMed
212241657Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.Lancet2002https://conductscience.org/library/papers/12241657PubMed
315374844A nested case-control study on treatment-related risk factors for early relapse of tuberculosis.Am J Respir Crit Care Med2004https://conductscience.org/library/papers/15374844PubMed
415533952In the treatment of tuberculosis, you get what you pay for...Am J Respir Crit Care Med2004https://conductscience.org/library/papers/15533952PubMed
516189810Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data.Stat Med2005https://conductscience.org/library/papers/16189810PubMed
618032770Statistics in medicine--reporting of subgroup analyses in clinical trials.N Engl J Med2007https://conductscience.org/library/papers/18032770PubMed
719542476Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.Am J Respir Crit Care Med2009https://conductscience.org/library/papers/19542476PubMed
824518046Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen.Respir Med2014https://conductscience.org/library/papers/24518046PubMed
925196020Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.N Engl J Med2014https://conductscience.org/library/papers/25196020PubMed
1025337748A four-month gatifloxacin-containing regimen for treating tuberculosis.N Engl J Med2014https://conductscience.org/library/papers/25337748PubMed
1125337749High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.N Engl J Med2014https://conductscience.org/library/papers/25337749PubMed
1226786954Sharing Clinical Trial Data--A Proposal from the International Committee of Medical Journal Editors.N Engl J Med2016https://conductscience.org/library/papers/26786954PubMed
1327353615mHealth for Tuberculosis Treatment Adherence: A Framework to Guide Ethical Planning, Implementation, and Evaluation.Glob Health Sci Pract2016https://conductscience.org/library/papers/27353615PubMed
1427516382Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.Clin Infect Dis2016https://conductscience.org/library/papers/27516382PubMed
1527776595Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis.Int J Tuberc Lung Dis2016https://conductscience.org/library/papers/27776595PubMed
1628045934Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.PLoS Med2017https://conductscience.org/library/papers/28045934PubMed
1728124478Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.Clin Pharmacol Ther2017https://conductscience.org/library/papers/28124478PubMed
1829326332The impact of digital health technologies on tuberculosis treatment: a systematic review.Eur Respir J2018https://conductscience.org/library/papers/29326332PubMed
197030377Whither short-course chemotherapy?Br J Dis Chest1981https://conductscience.org/library/papers/7030377PubMed

Download CSV of references

Cited by218

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 276 citations.

PMIDTitleJournalYearIn PapersSource
42971965Risk stratification for MDR/RR-TB: a comprehensive integrated patient-level analysis from TB programs and contemporary clinical trials.Nat Commun2026https://conductscience.org/library/papers/42971965PubMed
42935866Dried blood spot IP-10 as a biomarker of tuberculosis severity and treatment responses: results from a phase IIb trial of adjunctive acetylsalicylic acid and ibuprofen.Front Immunol2026https://conductscience.org/library/papers/42935866PubMed
42898291Prognostic utility of immune biomarkers for identifying individuals at risk of unfavourable treatment outcomes in pulmonary tuberculosis.Front Immunol2026https://conductscience.org/library/papers/42898291PubMed
42755735Treatment shortening and relapse control in drug-susceptible pulmonary tuberculosis: a network meta-analysis of randomized trials.Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42755735PubMed
42675628Single-Cell Immune Profiling Suggests Non-Classical Monocyte Is Associated Immunodepression in Tuberculosis Treatment Non-Responders.J Cell Mol Med2026https://conductscience.org/library/papers/42675628PubMed
42638666Ending tuberculosis: challenges and opportunities.Front Tuberc2024https://conductscience.org/library/papers/42638666PubMed
42638631
An integrated psycho-social intervention to improve self-efficacy toward TB treatment uptake and infection prevention among patients and family caregivers: a multicentric implementation research study protocol.
Front Tuberc2026https://conductscience.org/library/papers/42638631PubMed
42582131The PATHFAST TB LAM Ag assay: a validated protocol for quantitative tuberculosis treatment monitoring.Front Antibiot2026https://conductscience.org/library/papers/42582131PubMed
42576151Applying a Pharmacometrics-Enabled Machine Learning Analysis to Predict 2-Month Culture Conversion Using Phase 2a Data in a Tuberculosis Clinical Trial.Clin Transl Sci2026https://conductscience.org/library/papers/42576151PubMed
42477612Exposure to the four first-line anti-tuberculosis drugs and treatment outcomes: a target trial emulation study in Ghana.BMC Infect Dis2026https://conductscience.org/library/papers/42477612PubMed
42369478Within-host pathogen population diversity predicts treatment response in Tuberculosis.medRxiv2026https://conductscience.org/library/papers/42369478PubMed
42245132Transformer-based ensemble framework for tuberculosis treatment response prediction: multi-omics integration with clinical-grade performance.Front Mol Biosci2026https://conductscience.org/library/papers/42245132PubMed
42198395Is Short Therapy an Appropriate Regimen for Children and Young Adolescents with Drug-Susceptible Tuberculosis?Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42198395PubMed
42182461In vitro dormancy models improve ability to predict treatment response in severe marmoset tuberculosis lesions.bioRxiv2026https://conductscience.org/library/papers/42182461PubMed
42062935Socio-ecological vulnerability subgroups predict adherence and treatment outcomes in multidrug-resistant tuberculosis and HIV: a latent class analysis.BMC Infect Dis2026https://conductscience.org/library/papers/42062935PubMed
41994124Exposure to the Four First-Line Anti-Tuberculosis Drugs and Treatment Outcomes: A Target Trial Emulation Study in Ghana.Res Sq2026https://conductscience.org/library/papers/41994124PubMed
41989328Tuberculosis Disease Severity Assessment Using Clinical Variables and Radiology Enabled by Artificial Intelligence.J Infect Dis2026https://conductscience.org/library/papers/41989328PubMed
41946910Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.EMBO Mol Med2026https://conductscience.org/library/papers/41946910PubMed
41849373Effectiveness of routine tuberculosis education in a high-burden setting: A prospective observational cohort study.PLoS One2026https://conductscience.org/library/papers/41849373PubMed
41800241Exploring Host-driven Immunopathological Factors Developing Severe Tuberculosis: Insights from Comparative Mouse Models.Int J Biol Sci2026https://conductscience.org/library/papers/41800241PubMed

See all 218 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30397355

GET https://conductscience.org/api/papers/v1/30397355/cited_by?page=2